We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-15.77%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$54.8M
Cap. Flow
+$26.4M
Cap. Flow %
14.57%
Top 10 Hldgs %
55.68%
Holding
69
New
12
Increased
29
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$7.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.5M
3
MDVN
MEDIVATION, INC.
MDVN
+$2.46M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.28M
5
MRK icon
Merck
MRK
+$2.28M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.34M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.78M
3
TSRO
TESARO, Inc.
TSRO
+$1.76M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.59M
5
ESPR
Esperion Therapeutics
ESPR
+$1.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.5%
2 Miscellaneous 40.37%
3 Financials 0.14%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$53.7M 29.65%
862,500
+859,500
+28,650% +$67.7M
IBB icon
2
iShares Biotechnology ETF
IBB
$10.8B
$6.07M 3.35%
+60,000
New +$7.2M
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$5.39M 2.97%
58,567
+6,167
+12% +$534K
INCY icon
4
Incyte
INCY
$25.9B
$5.23M 2.89%
47,400
+5,527
+13% +$620K
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$5.16M 2.85%
33,021
+11,547
+54% +$2.11M
CELG
6
DELISTED
Celgene Corp
CELG
$5.1M 2.82%
47,137
+8,762
+23% +$1.09M
BIIB icon
7
Biogen
BIIB
$32.7B
$5.1M 2.81%
17,467
+6,213
+55% +$2.05M
ALKS icon
8
Alkermes
ALKS
$8.2B
$5.1M 2.81%
86,864
+15,842
+22% +$1.05M
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$5.03M 2.78%
118,372
+49,684
+72% +$2.46M
ILMN icon
10
Illumina
ILMN
$34.4B
$4.98M 2.75%
29,127
+7,075
+32% +$1.43M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$83.2B
$4.94M 2.73%
10,627
+1,868
+21% +$1M
NKTR icon
12
Nektar Therapeutics
NKTR
$2.55B
$4.87M 2.69%
29,617
+5,086
+21% +$900K
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$4.8M 2.65%
124,558
+20,219
+19% +$910K
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$12.6B
$4.42M 2.44%
42,012
+6,113
+17% +$817K
TECH icon
15
Bio-Techne
TECH
$11.4B
$4.35M 2.4%
188,000
+52,000
+38% +$1.3M
AZN icon
16
AstraZeneca
AZN
$255B
$4.33M 2.39%
68,000
+18,000
+36% +$1.18M
MTD icon
17
Mettler-Toledo International
MTD
$28.2B
$4.33M 2.39%
15,200
+4,200
+38% +$1.33M
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$139B
$4.26M 2.35%
40,876
+5,600
+16% +$719K
QGENF
19
DELISTED
QIAGEN NV
QGENF
$4.13M 2.28%
160,000
+20,000
+14% +$516K
IONS icon
20
Ionis Pharmaceuticals
IONS
$10.4B
$4.1M 2.26%
101,401
+35,193
+53% +$1.82M
CPHD
21
DELISTED
Cepheid Inc
CPHD
$4.07M 2.25%
90,000
+26,365
+41% +$1.41M
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$31.7B
$3.89M 2.15%
48,448
+13,469
+39% +$1.5M
AGIO icon
23
Agios Pharmaceuticals
AGIO
$2.05B
$3.25M 1.79%
+46,000
New +$4.5M
BMY icon
24
Bristol-Myers Squibb
BMY
$137B
$2.13M 1.18%
+36,000
New +$2.28M
MRK icon
25
Merck
MRK
$369B
$2.02M 1.12%
+42,968
New +$2.28M
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opus Point Partners Management held 69 positions worth $181M, up 43% from $126M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $26.4M of net new capital in Q3 2015, opening 12 new positions and adding to 29 existing holdings. Its largest new stake was iShares Biotechnology ETF: 60,000 shares worth $6.07M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $1.78M trimmed.

  • Opus Point Partners Management's largest Q3 2015 buy was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
  • Opus Point Partners Management added most to MEDIVATION, INC. in Q3 2015, an estimated $2.46M increase.
  • Opus Point Partners Management's biggest Q3 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $1.78M.
  • Opus Point Partners Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $5.34M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $181M portfolio in Q3 2015.
  • Opus Point Partners Management opened 12 new positions and closed 12 in Q3 2015.
  • Opus Point Partners Management's portfolio value rose 43% quarter-over-quarter to $181M.

Based on Opus Point Partners Management's 13F filing for Q3 2015, filed 16 Nov 2015.